Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Allon Therapeutics Inc.
Vancouver, British Columbia, Canadaallontherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Demonstrated statistically significant efficacy in Phase II clinical trials for amnestic mild cognitive impairment, showing 62.4% improvement in delayed-match-to-sample test and 17.2% increase in digit span test with high dose treatment. Received Orphan Drug Designation from FDA for davunetide in progressive supranuclear palsy.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesNeuroprotective peptides
- Industry
- Biotech
02
Partnerships
Nordic Biotech Venture Fund II K/S
Beyond the preview
Go deeper on Allon Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allon Therapeutics Inc..